



Changes of Small Non-coding RNAs by Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Wenzhe Wu¹, Eun-Jin Choi¹, Binbin Wang², Ke Zhang¹, Awadalkareem Adam², Gengming Huang³, Leo Tunkle^{4,5,6}, Philip Huang^{4,7}, Rohit Goru^{4,7}, Isabella Imirowicz^{4,7}, Leanne Henry^{4,6}, Inhan Lee⁴, Jianli Dong^{3,8}, Tian Wang^{2,3,8} and Xiaoyong Bao^{1,8,9}*

OPEN ACCESS

Edited by:

Hem Chandra Jha, Indian Institute of Technology Indore, India

Reviewed by:

Fumiaki Uchiumi, Tokyo University of Science, Japan Valeria Micheli, ASST Fatebenefratelli Sacco, Italy

> *Correspondence: Xiaoyong Bao xibao@utmb.edu

Specialty section:

This article was submitted to Molecular Diagnostics and Therapeutics, a section of the journal Frontiers in Molecular Biosciences

Received: 23 November 2021 Accepted: 19 January 2022 Published: 23 February 2022

Citation:

Wu W, Choi E-J Wang B, Zhang K, Adam A, Huang G, Tunkle L, Huang P, Goru R, Imirowicz I, Henry L, Lee I, Dong J, Wang T and Bao X (2022) Changes of Small Non-coding RNAs by Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Front. Mol. Biosci. 9:821137. doi: 10.3389/fmolb.2022.821137 ¹Department of Pediatrics, The University of Texas Medical Branch, Galveston, TX, United States, ²Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX, United States, ³Department of Pathology, The University of Texas Medical Branch, Galveston, TX, United States, ⁴miRcore, Ann Arbor, MI, United States, ⁵Department of Nuclear Engineering and Radiological Sience, University of Michigan, Ann Arbor, MI, United States, ⁶Department of Computer Science, University of Michigan, Ann Arbor, MI, United States, ⁷Department of Molecular, Cellular and Developmental Biology, University of Michigan, Ann Arbor, MI, United States, ⁸The Institute for Human Infections and Immunity, The University of Texas Medical Branch, Galveston, TX, United States, ⁹The Institute of Translational Sciences, The University of Texas Medical Branch, Galveston, TX, United States

The ongoing pandemic of coronavirus disease 2019 (COVID-19), which results from the rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a significant global public health threat, with molecular mechanisms underlying its pathogenesis largely unknown. In the context of viral infections, small non-coding RNAs (sncRNAs) are known to play important roles in regulating the host responses, viral replication, and host-virus interaction. Compared with other subfamilies of sncRNAs, including microRNAs (miRNAs) and Piwi-interacting RNAs (piRNAs), tRNA-derived RNA fragments (tRFs) are relatively new and emerge as a significant regulator of host-virus interactions. Using T4 PNK-RNA-seq, a modified next-generation sequencing (NGS), we found that sncRNA profiles in human nasopharyngeal swabs (NPS) samples are significantly impacted by SARS-CoV-2. Among impacted sncRNAs, tRFs are the most significantly affected and most of them are derived from the 5'-end of tRNAs (tRF5). Such a change was also observed in SARS-CoV-2-infected airway epithelial cells. In addition to host-derived ncRNAs, we also identified several small virus-derived ncRNAs (svRNAs), among which a svRNA derived from CoV2 genomic site 346 to 382 (sv-CoV2-346) has the highest expression. The induction of both tRFs and sv-CoV2-346 has not been reported previously, as the lack of the 3'-OH ends of these sncRNAs prevents them to be detected by routine NGS. In summary, our studies demonstrated the involvement of tRFs in COVID-19 and revealed new CoV2 svRNAs.

Keywords: SARS-CoV-2, TRF, SARS-CoV-2-derived sncRNAs, tRF5DC, viral replication and SARS-CoV-2-derived sncRNAs

INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a beta coronavirus belonging to the sarbecovirus subgenus of Coronaviridae family (Zhu et al., 2020). It is a positive-sense single-stranded RNA virus with a genome length of ~30 kb. By the middle of January 2022, the ongoing coronavirus disease 2019 (COVID-19) pandemic, caused by SARS-CoV-2, has respectively caused more than 320 million infectious cases and over five million deaths globally (World Health, 2021).

Small non-coding RNAs (sncRNAs) have diverse functions through various regulatory mechanisms. They virtually participate in all biological pathways, including cell proliferation, differentiation, apoptosis, autophagy, and tissue remodeling. sncRNAs are also essential to regulate host responses to viral infections (Choudhuri, 2010; Beermann et al., 2016; Romano et al., 2017; Rajput et al., 2020; Wu et al., 2020). Among sncRNAs, the most widely studied sncRNAs are microRNAs (miRNAs), which are 18–24 nt in length, carry 5' monophosphate and 3' hydroxyl (3'-OH) ends, and generally regulate genes *via* the argonaute (AGO) platform (Schwarz et al., 2004; Fabian and Sonenberg, 2012).

Other than miRNAs, piwi-interacting RNAs (piRNAs), small nucleolar RNAs (snoRNAs), and tRNA-derived RNA fragments (tRFs) are also important members of sncRNAs (Dozmorov et al., 2013). Currently, there is very limited information on whether or how SARS-CoV-2 regulates the sncRNA expression, except the reports on SARS-CoV-2-impacted miRNAs (Mallick et al., 2009; Hasan et al., 2014; Khan et al., 2020).

Using T4 polynucleotide kinase (T4 PNK)-RNA-seq, a modified next-generation sequencing (NGS), we found that tRFs and piRNAs were the two most abundant sncRNAs in nasopharyngeal swabs (NPS) samples of the SARS-CoV-2positive group. However, only tRFs were significantly enhanced in SARS-CoV positive samples. Generally, tRFs are generated by specific cleavages within pre-tRNAs or mature tRNAs (Lee et al., 2009). Compared with other sncRNAs, tRFs are relatively new members. However, their importance in diseases, such as cancer, infectious diseases, neurodegenerative diseases, and metabolic diseases, was quickly acknowledged after the discovery (Wang et al., 2013; Selitsky et al., 2015; Shen et al., 2018; Sun et al., 2018; Zhu et al., 2018; Choi et al., 2020; Qin et al., 2020; Wu et al., 2021). tRFs are classified mainly into tRF-1 series, tRF-3 series, and tRF-5 series (Fu et al., 2009). tRF-1 series are usually those from the 3'-trailer sequences of pre-tRNA, while tRF-3 and tRF-5 series are aligned to the 3'- and 5'- end of the mature tRNAs respectively. Among SARS-CoV-2-impacted tRFs, the most impacted tRFs belonged to tRF5s. In addition, the impacted tRF profile seemed to be SARS-CoV-2 specific, which is consistent with what we and others found previously on the changes in tRF signatures being virus-dependent (Wang et al., 2013; Selitsky et al., 2015), implicating tRFs as potential prognosis and diagnosis biomarkers. The impacted tRFs were also observed in SARS-CoV-2 infected human alveolar type II-like epithelial cells expressing human angiotensin-converting enzyme 2 (A549-ACE2) and human small airway epithelial cells (SAECs) in the air-liquid interface (ALI) culture.

In addition to host-derived ncRNAs, viral genomes can also encode ncRNAs. These viral ncRNAs vary in length and have diverse biological functions, including the regulation of viral replication, viral persistence, host immune evasion, host inflammatory response, and cell transformation (Tycowski et al., 2015). For example, SARS-CoV-encoded small RNAs contribute to SARS-CoV-induced lung injury (Morales et al., 2017), and SARS-CoV-2-encoded miRNAs enhance inflammation (Cheng et al., 2021). In this study, we revealed several new small viral RNA (svRNA) fragments, with the length of 25 nt, 33 nt, and 36 nt, by T4 PNK-RNA-seq. Among svRNAs derived from CoV-2 (sv-CoV2), a svRNA spanning from site 346 to site 382 of nsp1(sv-CoV2-346) had the highest expression.

In summary, this is the first report demonstrating the altered tRFs by SARS-CoV-2. T4 PNK pretreatment also enabled small RNA seq to reveal additional new sv-CoV2. In the future, we will characterize the biogenesis and function mechanisms of these new sncRNAs associated with SARS-CoV-2 infection.

MATERIALS AND METHODS

Nasopharyngeal Swab Specimens

NPS were collected from patients who visited outpatient clinics of the University of Texas Medical Branch (UTMB) for SARS-CoV-2 screening in April 2020. NPS samples in universal viral transport media were transported to the Molecular Pathology laboratory, directed by Dr. Jianli Dong, and subjected to SARS-CoV-2 test using Abbott m2000 SARS-CoV-2 RT-PCR assay. The limit of detection (LOD) of detection assays is 100 viral genome copies/ml.

Thirteen anonymous NPS samples were used in this study, including seven SARS-CoV-2 negative (51.7 ± 13.7 years old) and six SARS-CoV-2 positive (49.2 ± 10.5 years old) samples. The protocol was approved by the Institutional Review Boards (IRB) of UTMB at Galveston, under the IRB protocol # 02-089 and 03-385.

RNA Isolation

After the SARS-CoV-2 validation, 1 ml of NPS sample from each individual was subjected to RNA extraction using the mirVana PARIS kit (Invitrogen, MA, United States) according to the manufacturer's protocol. At the elution step, samples were incubated on the column for 5 min at 65°C, and the RNA was eluted with 45 μ L nuclease-free water. To extract RNAs from cells, TRIzol reagents (Thermo Fisher Scientific, MA, United States) were used for total RNA preparation, as described (Choi et al., 2020), followed by qRT-PCR.

T4 PNK-RNA-seq and Data Analyses

To study whether other sncRNAs than miRNAs are impacted by SARS-CoV-2, we used T4 PNK-RNA-seq, a modified NGS, to get sncRNA profiles for samples derived from NSP or cultured cells, similarly as described in (Honda et al., 2015; Giraldez et al., 2019). A flowchart of the T4 PNK-RNA-seq is shown in **Supplementary Figure S1A** and data have been deposited in GEO (GSE193555). Basically, we treated sample RNAs with T4 PNK before the



library construction and small RNA-seq to make the 3'-end of RNAs homogenous with -OH, as the ligation of the 3'-end of sncRNAs with sequencing barcodes requires the presence of 3'-OH and not all sncRNAs have 3-OH ends. The seq was done in the NGS Core of UTMB. In brief, the RNA samples were pretreated with 10 units of T4 PNK using 14 µL extracted RNAs in a final reaction volume of 50 µL and incubated at 37°C for 30 min, and then were heat-inactivated at 65°C for 20 min. The RNA was purified and concentrated within 6 µL nuclease-free water using Zymo RNA Clean and Concentrator kit (Irvine, CA, United States). Ligation-based small RNA libraries were prepared with an RNA input of 6 µL using NEB Next Multiplex Small RNA Library Prep Set for Illumina (Ipswich, MA, United States). Libraries were sequenced using the Illumina NextSeq 550 Mid-Output sequencing run. About 7,680 Mb of sequence data was generated.

To analyze the seq data, adaptor sequences were first removed using Cutadpat and reads with a length of more than 15 bp were extracted. We further filtered out RNAs with counts of less than 10 and all rRNA sequences, using the remainders as cleaned input reads. In terms of the mapping databases, we prepared tRF5 and tRF3 databases using the same sequences derived from different tRNAs [sequences downloaded from tRNA genes using the Table Browser of the UCSC genome browser (Karolchik et al., 2004)]. We also prepared tRF1 sequences using genome locations of tRNAs. Our in-house small RNA database includes 1) these tRFs, 2) miR/snoR sequences downloaded from the UCSC genome browser, and 3) piRNA sequences downloaded from piRBase (http://www.regulatoryrna.org/database/piRNA/). The cleaned input reads were mapped to our inhouse small RNA database using bowtie2 (v2.4.1) allowing two mismatches (option N -1). After we mapped the cleaned input reads to the small RNA database, the unmapped sequences were then mapped to the hg38 genome using the bowtie2 pre-built index (GRCh38_noalt_as) to detect all human sequences. The unmapped sequences to the human genome were then mapped to the SARS-CoV-2 reference genome (NC_045512) using the same parameters.

Raw read counts were normalized with the DEseq2 median of ratios method. Differentially expressed genes were determined by *p*-value < 0.05, fold change >2, and mean of normalized counts >10 in either Control (CN) or SARS-CoV-2 group. Unsupervised hierarchical clustering was performed using the Pearson correlation coefficient. A flowchart of the sequencing data analyses is summarized in **Supplementary Figure S1B**.

Cell Culture and Viruses

African green monkey kidney epithelial cells (Vero E6) were obtained from ATCC (Manassas, VA, United States) and maintained in a high-glucose DMEM (Gibco, MA, United States) supplemented with 10% fetal bovine serum (FBS), 10 units/ml penicillin, and 10 μ g/ml streptomycin. The human alveolar type II-like epithelial cells expressing human angiotensin-converting enzyme 2 (A549-ACE2) cells were a kind gift from Dr. Shinji Makino and were cultured in DMEM (Gibco,

TABLE 1	Sequence	information	for tRE5s	RNA linker	RT primer	aPCB	primers and	PCR	nrimers
	Dequence	inionnation	101 11 103,		n piine	, yr on	primers and	I OII	princio

tRFs		Sequence (5'-3')
tRF5-GlyGCC	tRFs	GCAUUGGUGGUUCAGUGGUAGAAUUCUCGCC
	Forward primer	GCATGGGTGGTTCAGTG
	Reverse primer	CGTCGGACTGTAGAACTCTCAAAGC
tRF5-GluCTC	tRFs	UCCCUGGUGGUCUAGUGGUUAGGAUUCGGCGCU
	Forward primer	TCCCTGGTGGTCTAGTG
	Reverse primer	CGTCGGACTGTAGAACTCTCAAAGC
tRF5-LysCTT	tRFs	GCCCGGCUAGCUCAGUCGGUAGAGCAUGAGACU
	Forward primer	GCCCGGCTAGCTCAGTCGGTAG
	Reverse primer	CGTCGGACTGTAGAACTCTCAAAGC
tRF5-ValCAC	tRFs	GUUUCCGUAGUGUAGUGGUUAUCACGUUCGCU
	Forward primer	GTTTCCGTAGTGTAGTGGTTATC
	Reverse primer	CGTCGGACTGTAGAACTCTCAAAGC
tRF5-CysGCA	tRFs	GGGUAUAGCUCAGUGGUAGAGCAUUUGACUGC
	Forward primer	AGTGGTAGAGCATTTGACTGC
	Reverse primer	CGTCGGACTGTAGAACTCTCAAAGC
tRF5-GInCTG	tRFs	UGGUGUAAUAGGUAGCACAGAGAAUUCUGG
	Forward primer	GGTGTAATAGGTAGCACAGAG
	Reverse primer	CGTCGGACTGTAGAACTCTCAAAGC
5sRNA	Forward primer	GGGAATACCGGGTGCTGTAGG
	Reverse primer	CGTCGGACTGTAGAACTCTCAAAGC
U6	Forward primer	GATGACACGCAAATTCGTGAAGCG
	Reverse primer	CGTCGGACTGTAGAACTCTCAAAGC
3'RNA linker		/5Phos/GAACACUGCGUUUGCUGGCUUUGAGAGUUCUACAGUCCGACGAUC/3ddC/
RT primer		CGTCGGACTGTAGAACTCTCAAAGC
CoV2-346	CoV2-346	CGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUU
	RT primer	CGTCGGACTGTAGAACTCTCAAAGC
	Forward primer	ACGACGTACGTGGCTTTG
	Reverse primer	GCAAACGCAGTGTTCAAGA

MA, United States) containing 10% FBS, 10 units/ml penicillin, and 10 $\mu g/ml$ streptomycin.

Small airway epithelial cells (SAECs), isolated from the normal distal portion of the lung in the 1 mm bronchiole area, were purchased from Lonza (Basel, Switzerland) to generate cells in the air-liquid interface (ALI) culture. The cells were cultured and differentiated using Complete PneumaCult[™]-Ex plus medium and PneumaCult[™]-ALI-S Maintenance medium (Stemcell Technologies, Vancouver, Canada), respectively, according to the manufacturer's instructions.

Briefly, the cells at passage two (P2) were expanded in the T-25 flask using the complete PneumaCultTM-Ex plus medium, with a medium change every other day. For ALI cultures, the cells (P3) were seeded into Corning Costar 12 mm transwell inserts (Corning, NY, United States) at a concentration of 11×10^4 cells/insert in 0.5 ml medium/insert, and another 1 ml/well medium was added to the basal chamber. Cells were submerged cultured in Complete PneumaCultTM-Ex plus medium, with a medium change every other day. After reaching ~100% confluency, ALI was initiated by removing the apical medium and replacing the PneumaCultTM-Ex plus medium in the basal compartment with PneumaCultTM-Ex plus medium in the basal compartment with PneumaCultTM-Ex plus medium. The basal compartment medium was changed every other day. It took about 21 days to complete cell differentiation.

SARS-CoV-2 (USA-WA1/2020 strain) was obtained from the World Reference Center for Emerging Viruses and Arboviruses (WRCEVA) at the UTMB. Viral stocks were prepared by propagation in Vero E6 cells. Viral titers were determined by plaque assay as described (Blanco-Melo et al., 2020). All experiments using live SARS-CoV-2 were performed in a biosafety level 3 (BSL-3) laboratory with redundant fans in the biosafety cabinets. All personnel wore powered air-purifying respirators (Breathe Easy, 3M) with Tyvek suits, aprons, booties, and double gloves. All cell cultures, cell lines or primary cultured cells, and viruses have been approved for use by the Institutional Biosafety Committee of UTMB (NOU# 2018056 and NOU# 2020043).

Viral Infection

To infect A549-ACE2 cells in monolayer culture, the cells were seeded into the 24-well plate 24 h prior to the infection to allow the cells to reach 80–90% confluence in the following day. For infection, the cells were incubated with viruses in DMEM media with 10% FBS at a multiplicity of infection of 0.1 (MOI = 0.1). After 1 h incubation, cells were washed with PBS three times to remove the remaining viruses and cultured in fresh media containing 10% FBS. The cells were collected on day 4 post-infection.

Regarding the infection of SAECs in ALI culture, the infection was performed when hallmarks of excellent differentiation were evident, such as extensive apical coverage with cilia. Prior to infection, the apical side of the cells was washed five times with PBS, and the basal surface was washed once with PBS. Viruses were diluted to the specified MOI in 200 μ L MEM medium and inoculated onto the apical surface of the ALI cultures. After a 2-h



incubation at 37°C with 5% CO_2 , unbound viruses were removed by washing the surface with PBS three times. The cells were collected on day 1 or 3 post-infection. The SARS-CoV-2 S gene was detected using qRT-PCR with primers as follows: S forward primer, 5' CCTACTAAATTAAATGATCTCTGCTTTACT; reverse primer, 5' CAAGCTATAACGCAGCCTGTA.

qRT-PCR and RT-PCR

To evaluate sncRNAs expression, qRT-PCR was performed, as described previously (Choi et al., 2020; Wu et al., 2021). A schematic summary of tRF quantification by qRT-PCR is shown in the left panel of Figure 1A. Briefly, the total RNA was treated with T4 PNK, and then ligated to a 3'-RNA linker using T4 RNA ligase from Thermo Fisher Scientific (Waltham, MA, United States). The product was used as a template for reverse transcription (RT) with a linker-specific reverse primer using TaqMan Reverse Transcription Reagents from Thermo Fisher Scientific. The cDNA was subjected to SYBR Green qPCR using iTaq[™] Universal SYBR Green Supermix kit from Bio-Rad (Hercules, CA, United States) and primers specific to the 5'-end of tRFs and RNA linker. U6 was used for normalization. The addition of a 3'-RNA linker enables the detection of tRF5s without the signal interference from its corresponding parent tRNAs, possibly because 1) the 3-end of tRNA is usually attached with an amino acid, preventing RNA linker attachment, and 2) reverse transcription annealing temperature sets tRFs, not tRNAs, to be annealed by the primer, as tRNA cloverleaf structure requires a specific denaturing temperature before annealing (right panel of **Figure 1A**) (Choi et al., 2020; Wu et al., 2021). The primers and 3'-RNA linker sequences are listed in **Table 1**.

To validate the seq data of CoV2-encoded small RNAs (CoV2-346), RT-PCR was performed, using RT and PCR primers listed in **Table 1**. The overall experimental design to detect CoV2-346 by RT-PCR is illustrated in **Figure 1B**, with detailed seq information of primers and the RNA linker shown in **Figure 1C**. In brief, RNAs, pretreated with or without T4 PNK, were ligated to a 3'-RNA linker. The RT was done using primers complementary to the RNA linker, followed by PCR using forward primers annealing to 5'-end of CoV2-346 and reverse primers annealing to the last 4 nt of CoV2-346 and the first 15 nt of RNA linker.

Northern Blot

Northern hybridization for tRF5-GluCTC was performed as described (Wang et al., 2013). Briefly, $3 \mu g$ RNA was loaded on 15% denaturing polyacrylamide gel with 7 M ureas and then transferred to a positively charged nylon membrane (Amersham Biosciences, NJ, United States). The membrane was hybridized with a ³²P-labeled DNA probe in ULTRAhyb-Oligo solution (Life Technologies, Grand Island, NY, United States), followed by

TABLE 2 | Changes in tRFs by SARS-CoV-2.

	Mean		Log2FC	Fold Change (FC)	p-value	Padj
	CN	COVID-19				
Down-regulated						
tRF1_chr5_24_Lys_CTT_26198538	19.94	1.62	-3.65	12.54	0.00607	0.02862
Up-regulated						
tRF5-Val-TAC-1-2	1.43	32.82	4.31	19.79	0.00047	0.00439
tRF5-Val-CAC-chr1-93	65.75	869.52	3.72	13.20	0.00056	0.00498
tRF5-Val-CAC-3-1	3.38	27.07	2.86	7.26	0.00781	0.03457
tRF5-Val-CAC-2-1	6.11	120.86	4.34	20.25	0.00010	0.00151
tRF5-Und-NNN-4-1	9.13	128.84	3.79	13.85	0.00007	0.00117
tRF5-Thr-CGT-6-1	5.28	95.45	4.08	16.86	0.00019	0.00220
tRF5-Ser-CGA-2-1	0.92	10.74	4.81	28.14	0.00112	0.00798
tRF5-SeC-TCA-2-1	41.06	609.64	3.94	15.34	0.00006	0.00099
tRF5-nmt-Gln-TTG-6-1	0.39	21.22	5.23	37.52	0.00079	0.00632
tRF5-Lys-CTT-chr15-5	0.45	14.56	4.60	24.24	0.00389	0.02083
tRF5-Lys-CTT-6-1	27.07	118.09	2.09	4.27	0.01283	0.04915
tRF5-Lys-CTT-3-1	13.01	199.40	3.89	14.80	0.00005	0.00089
tRF5-Lys-CTT-2-5	40.64	667.89	4.03	16.29	0.00000	0.00006
tRF5-Leu-TAG-3-1	2.23	73.96	5.23	37.54	0.00000	0.00003
tRF5-Leu-CAG-2-1	2.55	32.99	3.57	11.84	0.00132	0.00913
tRF5-Leu-AAG-3-1	7.52	247.62	5.12	34.87	0.00000	0.00000
tRF5-iMet-CAT-1-8	3.33	109.22	4.89	29.56	0.00001	0.00017
tRF5-His-GTG-2-1	3.93	34.02	3.00	8.03	0.01555	0.05736
tRF5-Gly-CCC-6-1	4.71	20.69	2.14	4.39	0.02402	0.07725
tRF5-Glu-TTC-chr1-138	82.66	458.76	2.48	5.59	0.00270	0.01595
tRF5-Glu-IIC-8-1	140.13	1637.50	3.54	11.63	0.00028	0.00287
tRF5-Glu-TTC-1-2	13.42	47.61	1.85	3.60	0.04498	0.12120
tRF5-Glu-CIC-3-1	1.18	12.02	4.17	18.05	0.00619	0.02892
tRF5-Glu-CTC-2-1	8234.45	83040.94	3.33	10.08	0.00012	0.00173
tRF5-Ala-TGC-3-2	3.89	27.72	2.98	7.89	0.01629	0.05924
TRF5-Ala-CGC-3-1	2.93	29.71	3.41	10.60	0.00335	0.01915
TRF5-Ala-CGC-2-1	1.59	27.28	3.95	15.42	0.00182	0.01173
TRF5-Ala-AGC-4-1	2.44	27.91	3.41	10.62	0.00566	0.02723
tRF3-Val-TAC-3-1	1.08	49.08	5.17	35.90	0.00001	0.00024
IRF3-Val-TAG-T-2	3.11	79.20	4.47	22.16	0.00002	0.00040
tRF3-Val-CAC-cnr1-93	0.72	47.24	5.62	49.09	0.00001	0.00018
10F3-Val-AAC-4-1	0.16	43.10	4.01	28.00	0.00008	0.00122
tPE2 Trp CCA 4 1	0.10	112.24	5.45	43.78	0.00011	0.00130
tDE2 Thr TOT 5 1	2.40	26.02	0.60	614	0.00000	0.00001
tPE2 Thr CCT 4 1	1.04	14 12	2.02	7.24	0.01042	0.00924
tPE2 Thr CCT 2 1	0.50	10.11	2.00	12.04	0.00506	0.09972
tBE3-Thr-CGT-1-1	0.09	12.25	5.09	54 09	0.00090	0.02000
tPE2 Thr ACT 5 1	0.00	10.94	1.24	20.24	0.00010	0.00101
tBE3-Thr-AGT-4-1	0.49	12.04	4.04	20:24	0.00110	0.00023
tBE3-Thr-AGT-3-1	0.33	12.77	4.50	22.66	0.00004	0.00400
tBE3-SeC-TCA-2-1	2.95	128.28	5.28	38.72	0.00000	0.00002
tBE3-Pro-TGG-3-5	38.00	215.39	2.53	5.77	0.00515	0.02533
tBE3-Phe-GAA-10-1	4 75	119.56	4 54	23.34	0.00001	0.00033
tRE3-nm-Tvr-GTA-chr21-2	2.28	12.21	2.29	4.90	0.03717	0.10322
tRF3-nmt-Gln-TTG-9-1	7.30	276.42	5.16	35.76	0.00000	0.00001
tBE3-nmt-Gln-TTG-7-1	7.17	278.12	5.15	35.42	0.00000	0.00001
tRF3-Lvs-TTT-14-1	4.97	73.70	3.84	14.29	0.00686	0.03108
tRF3-Lvs-CTT-9-1	0.00	10.54	5.54	46.55	0.00011	0.00163
tRF3-Leu-TAG-3-1	6.59	143.71	4.32	20.02	0.00001	0.00024
tRF3-Leu-TAG-2-1	15.06	196.02	3.74	13.35	0.00006	0.00099
tRF3-Leu-TAG-1-1	3.46	72.59	4.61	24.39	0.00005	0.00089
tRF3-Leu-CAG-chr9-7	6.77	50.14	2.95	7.74	0.01033	0.04250
tRF3-Leu-CAG-1-6	7.52	51.42	2.93	7.64	0.00670	0.03063
tRF3-Leu-AAG-7-1	2.89	45.39	3.81	14.06	0.00025	0.00271
tRF3-Leu-AAG-2-4	14.00	184.25	3.75	13.46	0.00001	0.00017
tRF3-iMet-CAT-1-6	0.52	15.97	4.67	25.41	0.00067	0.00567
tRF3-Gly-TCC-2-5	1.86	201.79	6.53	92.33	0.00000	0.00000
tRF3-Gly-CCC-7-1	14.44	134.89	3.22	9.29	0.00075	0.00611
tRF3-Gln-TTG-3-3	1.08	12.93	3.26	9.57	0.00691	0.03113

(Continued on following page)

TABLE 2 | (Continued) Changes in tRFs by SARS-CoV-2.

	Mean		Log2FC	Fold Change (FC)	p-value	Padj
	CN	COVID-19				
tRF3-Gln-CTG-5-1	0.82	12.55	3.63	12.37	0.00186	0.01193
tRF3-GIn-CTG-1-5	0.23	19.81	5.73	53.01	0.00007	0.00108
tRF3-Cys-GCA-9-4	0.33	14.30	4.70	26.06	0.00061	0.00525
tRF3-Cys-GCA-5-1	0.82	15.93	3.98	15.77	0.00106	0.00777
tRF3-Cys-GCA-4-1	0.69	16.86	4.33	20.09	0.00059	0.00514
tRF3-Cys-GCA-24-1	0.71	15.60	4.20	18.42	0.00082	0.00645
tRF3-Cys-GCA-23-1	0.62	21.73	4.77	27.20	0.00023	0.00257
tRF3-Cys-GCA-21-1	0.16	19.72	5.74	53.58	0.00006	0.00095
tRF3-Cys-GCA-17-1	1.10	19.03	3.89	14.79	0.00084	0.00657
tRF3-Cys-GCA-10-1	0.26	14.50	5.26	38.21	0.00018	0.00211
tRF3-Arg-TCT-1-1	2.49	118.78	5.66	50.51	0.00000	0.00001
tRF3-Arg-CCT-5-1	1.58	12.23	2.77	6.84	0.03258	0.09412
tRF3-Arg-CCT-4-1	2.60	13.48	2.19	4.57	0.03323	0.09521
tRF3-Arg-CCG-2-1	4.96	61.43	3.51	11.36	0.00072	0.00595
tRF3-Ala-TGC-4-1	1.46	30.32	4.16	17.91	0.00033	0.00320
tRF3-Ala-TGC-3-1	3.57	44.92	3.53	11.52	0.00091	0.00693
tRF3-Ala-TGC-2-1	0.91	75.23	6.13	70.14	0.00000	0.00001
tRF3-Ala-TGC-1-1	0.16	58.71	7.31	159.08	0.00000	0.00001
tRF3-Ala-CGC-4-1	14.18	93.77	2.66	6.30	0.00456	0.02318
tRF3-Ala-AGC-4-1	0.98	80.87	6.19	72.78	0.00000	0.00001
tRF3-Ala-AGC-2-2	14.67	92.70	2.60	6.07	0.00638	0.02969
tRF1_chr2_6_Glu_TTC_75124115	0.00	13.35	5.86	58.15	0.00022	0.00249

membrane washing and image development. The ³²P-labeled DNA probe for tRF5-GluCTC was 5'-CGCCGAATCCTAACC ACTAGACCACCA-3'.

Statistical Analysis

The experimental results were analyzed using Graphpad Prism 5 software. To compare the sncRNAs expression of NPS between SARS-CoV-2 negative and positive groups, an unpaired two-tailed Mann-Whitney *U* test was used. To compare the sncRNAs expression in SARS-CoV-2 infected cells and mock-infected cells, an unpaired two-tailed *t*-test was employed. A *p*-value < 0.05 was considered to indicate a statistically significant difference. Single and two asterisks represent a *p*-value of <0.05 and <0.01, respectively. Means \pm standard errors (SE) are shown.

RESULTS

T4 PNK-RNA-seq Revealed SARS-CoV-2-Impacted sncRNAs in NPS Samples.

To identify SARS-CoV-2-impacted sncRNAs, we initialized T4 PNK-RNA-seq for the NPS samples from four SARS-CoV-2 positive patients with their ages at 54.3 ± 4.0 years old and four SARS-CoV-2 negative subjects, with matched age at 50.5 ± 10.2 years old. The seq data were analyzed similarly as described in (Wang et al., 2013; Liu et al., 2018). In brief, the sequences with length >15 bp and reads >10 were mapped to the in-house small RNA database containing tRFs, miR/ snoRs, and piRs to address redundant tRNA sequences across the genome after removing rRNAs. Unmapped sequences were then mapped to the hg38 human genome to identify other human-derived sequences and their composition. We

found that piRNAs and tRFs were the two most abundant sncRNAs in SARS-CoV-2 positive samples. The top-10 ranked piRNAs and tRFs in the SARS-CoV-2 positive group are listed in **Supplementary Tables S1, S2**, respectively. As shown in **Supplementary Table S2**, all tRFs were derived from the 5'-ends of tRNAs, therefore tRF5s. Compared with the tRFs and piRNAs, the overall reads of miRNAs were much less (**Figure 2A**). We also compared the sncRNA profiles between SARS-CoV-2 positive and negative samples. As shown in **Figure 2A**, while the tRFs consisted of about 14% of all sncRNA counts in the control group, tRFs counts became 42% in the COVID-19 group, demonstrating a significant increase by COVID-19. In contrast, the overall expression of miRNAs and piRNAs was not impacted by COVID-19 (**Figure 2A**).

Differential expression analysis for individual sncRNAs was also performed for SARS-CoV-2 negative and positive groups. As shown in **Figure 2B**, there were more up-regulated tRFs than down-regulated tRFs, while SARS-CoV-2 down-regulated snoRNAs were more than up-regulated ones. We also listed sncRNAs, which were significantly altered by SARS-CoV-2 in **Tables 2–4**. The cutoff was set as a fold change >2, with the significance of p < 0.05 in changes by SARS-CoV-2, and the mean of normalized counts >10 in the negative or positive group. The differentially expressed tRFs, miRNAs, and snoRNAs were listed in **Tables 2–4**, respectively.

As shown in **Table 2**, tRFs were significantly impacted by SARS-CoV-2 in NPS. Among those, 2 tRFs belong to the tRF1 series, 28 tRFs were tRF5s, and 53 tRFs were tRF3s. However, top-ranked SARS-CoV-2-impacted tRFs all belong to the tRF5. In **Figure 2C**, the mean of normalized counts >20 in the control (CN) or SARS-CoV-2 positive (SARS-CoV-2) group were

TABLE 3 | Changes in miRNAs by SARS-CoV-2.

		Mean	Log2FC	Fold Change (FC)	<i>p</i> -value	Padj
	CN	COVID-19				
Up-regulated						
hsa-miR-4443	1.99	497.56	8.16	286.11	3.6E-11	1.5E-08
hsa-miR-12116	0.23	36.13	6.57	95.26	9.1E-06	0.00024
hsa-miR-765	0.00	14.76	6.02	65.02	0.00027	0.00282
hsa-miR-1224-3p	0.00	13.04	5.84	57.20	0.00014	0.00181
hsa-miR-6880-3p	0.00	12.98	5.83	56.87	0.00012	0.00165
hsa-miR-6886-3p	0.00	11.95	5.71	52.37	0.00017	0.00202
hsa-miR-6758-5p	0.16	19.09	5.68	51.37	0.00019	0.0022
hsa-miR-4716-5p	0.00	11.28	5.64	49.85	0.00032	0.00317
hsa-miR-1281	0.00	10.01	5.45	43.62	0.00137	0.0093
hsa-miR-6741-3p	0.45	23.94	5.31	39.69	7.7E-05	0.00122
hsa-miR-769-5p	0.26	14.85	5.31	39.64	0.00013	0.00181
hsa-miR-877-3p	1.17	54.42	5.26	38.26	1.5E-05	0.00033
hsa-miR-1469	0.16	13.97	5.26	38.23	0.00164	0.01068
hsa-miR-10401-5p	1.58	59.29	5.07	33.70	0.00067	0.00567
hsa-miR-7111-3p	0.23	12.72	5.07	33.59	0.00073	0.00597
hsa-miR-4646-3p	0.23	10.42	4.78	27.49	0.00106	0.00777
hsa-miR-204-3p	0.66	24.52	4.73	26.59	0.0005	0.00463
hsa-miR-7107-5p	2.14	59.30	4.62	24.67	0.00018	0.00215
hsa-miR-6510-5p	0.49	17.34	4.55	23.44	0.00052	0.00473
hsa-miR-6823-3p	0.85	23.17	4 48	22.27	0.00048	0.00441
hsa-miR-3196	8 17	141 16	4 04	16.41	0.0004	0.00389
hsa-miR-665	0.78	14 73	3.89	14 79	0.00153	0.0102
hsa-miR-7847-3p	2.36	30.55	3.53	11.52	0.00358	0.01993
hsa-miR-1268h	3.52	32.94	3.05	8.30	0.00432	0.02222
hsa-miR-139-3n	1.28	12.34	3.00	7 98	0.01266	0.02222
hsa-miR-4728-5n	1.10	10.31	2.98	7.89	0.01414	0.05307
hsa-miR-320c	8.22	62.47	2.85	7.20	0.00743	0.03314
hsa-miR-92b-5n	87 47	600.46	2.00	6.80	0.00429	0.02216
hsa-miR-320h	13.69	93.88	2.71	6.56	0.00109	0.02210
hsa-miR-140-3n	1.48	11 69	2.71	6.49	0.00100	0.00700
hsa-miR-186-5n	6.64	39.95	2.46	5 50	0.02296	0.00210
hsa-miR-378a-3n	9.29	50.19	2.40	5.07	0.02230	0.07477
hsa-miR-1268a	5.61	27.61	2.04	4.43	0.02425	0.06879
hsa-miR-762	5.81	27.01	2.13	4.45	0.02000	0.00073
hsa-miR-2110	8.28	38.68	2.10	4.00	0.00074	0.03333
Down-regulated	0.20	00.00	2.12	4.00	0.02247	0.07400
bea miP 34b 3p	12 02	1 10	5.20	26.68	0.0003	0.00206
hsa-miP 328 2p	40.92	2.29	-0.20	7.60	0.0003	0.00000
hsa-miR 6510 2n	15.96	1.64	-2.95	0.54	0.02050	0.00900
hsa-miR-26a-5n	1/3 78	25.03	-3.25	5.04	0.01168	0.04000
haa miP 00a 5n	657 50	160.00	-2.40	J.40 A 02	0.01000	0.00740
hea miD 00h on	246.00	100.20	-2.01	4.03	0.01072	0.00040
hsa-miR-92b-3p	346.22	42.48	-3.02	8.12	0.00127	(

selected to plot the heatmap and their sequences were listed in Table 5.

Experimental Validation of SARS-CoV-2-Impacted tRFs

To validate the seq data, we used modified qRT-PCR to detect the expression of tRF5-GluCTC, tRF5-LysCTT, and tRF5-ValCAC, three top-ranked tRF5s in SARS-CoV-2-positive patients according to the seq data, as we previously described (Choi et al., 2020; Wu et al., 2021). Compared with Northern blot validation, the modified qRT-PCR with T4 PNK pretreatment and 3'-end RNA linker ligation provides the possibility to validate as many tRFs as possible for NPS samples, which usually have a limited yield of RNAs. Our results demonstrated that tRF5-

GluCTC, tRF5-LysCTT, and tRF5-ValCA were significantly increased in the SARS-CoV-2 group (**Figures 3A–C**). Unlike SARS-CoV-2, which could induce tRF5-ValCAC, respiratory syncytial virus (RSV), a negative-sense RNA virus, does not induce tRF5-ValCAC infected cells (Wang et al., 2013), suggesting the change in tRF profile in response to viral infections is virus-specific.

Other than the three tRF5s mentioned above, tRF5-CysGCA, tRF5-GlnCTG and tRF5-GlyGCC were also chosen for the validation, as these three tRFs are highly inducible by RSV with the function tRF5-GlyGCC and tRF5-GlnCTG being vital in promoting RSV replication (Choi et al., 2020; Zhou et al., 2017). Although the function of tRF5-CysGCA in RSV is not clear in viral infection, it is important in regulating stress responses and neuroprotection (Ivanov et al., 2014). We validated that tRF5-

TABLE 4 | Changes in snoRNAs by SARS-CoV-2.

	Mean		Log2FC	Fold Change (FC)	<i>p</i> -value	Padj
	CN	COVID-19				
Down-regulated						
hg38_wgRna_ACA49	227.26	0.27	-9.25	609.86	1.9E-09	3.4E-07
hg38_wgRna_ACA40	180.98	0.53	-8.40	338.05	1.7E-09	3.4E-07
hg38_wgRna_ACA28	219.23	0.72	-8.22	299.21	8.6E-09	1.1E-06
hg38_wgRna_ACA8	409.75	8.53	-5.57	47.58	9.1E-08	7.7E-06
hg38_wgRna_U92	79.97	1.72	-5.49	44.82	2.1E-06	8E-05
hg38_wgRna_E3	162.73	3.73	-5.41	42.66	4.4E-08	4.7E-06
hg38_wgRna_ACA25	38.67	0.92	-5.31	39.75	3.6E-05	0.00069
hg38_wgRna_ACA16	158.54	4.34	-5.13	34.92	2E-08	2.3E-06
hg38_wgRna_ACA3	206.55	7.70	-4.74	26.71	2E-05	0.00042
hg38_wgRna_U73a	25.28	1.01	-4.62	24.63	0.00062	0.00531
hg38_wgRna_U35A	99.03	4.05	-4.58	23.87	4.2E-07	2.1E-05
hg38 wgRna ACA38	35.59	1.45	-4.53	23.09	0.00024	0.00258
hg38 wgRna mgU6-77	93.30	4.01	-4.50	22.65	7.6E-06	0.0002
hg38 wgRna HBII-82B	36.20	1.76	-4.50	22.57	0.00015	0.00187
hg38 wgRna E2	88.91	4.05	-4.48	22.26	4.5E-05	0.00087
ha38 waRna ACA63	122.12	5.51	-4.45	21.84	0.00016	0.00192
hg38 wgRna HBII-180A	157.02	7.50	-4.39	21.04	4E-06	0.00013
hg38 wgRna U71a	38.72	1.83	-4.39	20.95	0.00019	0.00221
hg38 wgRna ACA41	21.63	1.00	-4.31	19.86	0.00372	0.02024
hg38 wgRna U90	86.50	4.66	-4.18	18.07	5E-05	0.00089
hg38 wgRna ACA10	38.56	2.01	-4.15	17.73	0.00162	0.0106
hg38 wgBna U97	89.21	4.93	-4 14	17.68	0.00013	0.00181
hg38 wgRna ACA44	114.67	7.12	-3.97	15.72	1.1E-05	0.00027
hg38 wgBna ACA9	13.58	1.00	-3.75	13.48	0.00509	0.02516
hg38 wgBna ACA51	85.91	6.42	-3.72	13.16	0.0003	0.00306
hg38 wgBna ACA3-2	124 34	9.63	-3.68	12 78	0.00082	0.00645
hg38 wgBna U15A	87.31	6.73	-3.67	12.73	0.00036	0.00352
hg38 wgBna L15B	37.76	3.37	-3.53	11 57	0.00156	0.01027
hg38 wgBna ACA1	28.02	2.69	-3.43	10.81	0.00929	0.0395
hg38 wgBna ACA53	62 15	5.85	-3.41	10.60	0.0027	0.01595
hg38 wgBna SNOBD123	21 14	2 10	-3.36	10.30	0.00525	0.02556
hg38 wgBna U17b	86.15	8.67	-3.32	10.02	0.00015	0.00184
hg38 wgBna ACA6	31.12	3 13	-3.31	9.89	0.00373	0.02024
hg38 wgBna Ll34	33.68	3.92	-3.15	8.87	0.00076	0.02024
hg38 wgBna Ll18B	16.65	1.90	-3.07	8.38	0.00200	0.04479
hg38 wgRna SNORA38B	13.00	1.00	_2.01	7 49	0.01166	0.05743
hg38 wgRna LI32A	70.17	9.50	_2.86	7.40	0.01000	0.00740
hg38 wgRna 1152	/1.02	6.17	-2.00	6.92	0.00013	0.00001
hg38 wgRna U51	-+ 1.32 26 72	0.17 A 02	-2.13	6.73	0.00070	0.09990
hgoo_wgnha_oot hg38_wgRpa_L117a	20.75	4.02	-2.13	6.73	0.02101	0.07241
hg00_wg111a_017a	20.10	4.40	-2.04	5.76	0.00479	0.02090
hgoo_wgnha_i iDii-oo-io haaa waRna 1110 0	18 22	0.01	-2.00	4.00	0.02709	0.00440
11900_wyn11a_019-2	10.00	4.00	-2.00	4.00	0.04700	0.12008

CysGCA and tRF5-GlnCTG were also significantly enhanced in the SARS-CoV-2 group, compared with the control (CN) group (**Figures 3D,E**). However, SARS-CoV-2 did not affect tRF5-GlyGCC expression (**Figure 3F**). Given the fact that RSV induces significantly tRF5-GlyGCC (Wang et al., 2013), the result of **Figure 3F** supported virus-specific induction of tRFs and tRFs as potential biomarkers of viral infection.

Impacted tRFs in SARS-CoV-2-Infected Cells

A549-ACE2 is a common cell model to study coronaviruses, such as SARS-CoV and SARS-CoV-2 (Mossel et al., 2005; Blanco-Melo et al., 2020; Weston et al., 2020; Buchrieser et al., 2021). Herein, we studied whether the induction of tRFs can be recapitulated in SARS-CoV-2-infected A549-ACE2. As shown in **Figures 4A–E**, A549-ACE2 cells, at day 4 post-infection (p.i.) of SARS-CoV-2, had dramatically induction of tRF5-GluCTC, tRF5-LysCTT, tRF5-ValCAC, tRF5-CysGCA, and tRF5-GlnCTG. The northern blot also confirmed the induction of tRF5-GluCTC (**Figure 4F**), which was the most abundant tRF5 among the tested four tRF5s, confirming the liability of our newly developed qRT-PCR.

We also used primary SAECs in ALI culture, a commonly acknowledged physiology airway infection model (Bhowmick and Gappa-Fahlenkamp, 2016; Chandorkar et al., 2017), to confirm SARS-CoV-2-affected tRFs. SAECs, after a few weeks of ALI culture, have been shown to establish a pseudostratified cell layer that resembles the small airway epithelium as found *in vivo* (Hiemstra et al., 2018). Moreover, SAECs in ALI cultures

TABLE 5	tRE5s with	mean of	normalized	counts >	20 in	Control	(CN) or	· COVID-19	arouns
	11103 11111	moun or	nonnaizea	0001113 >	20 111	00111101		0010 10	groups.

Mean		ean	Log2FC Fold	<i>p</i> -value	Padj	Sequence	Length	
	CN	COVID- 19		Change (FC)				(nt)
Up-regulated								
tRF5-Ala-TGC-3-2	3.89	27.72	2.98	7.89	0.01629	0.05924	GGGGAUGUAGCUCAGUGGC	19
tRF5-Ala-CGC-3-1	2.93	29.71	3.41	10.60	0.00335	0.01915	GGGGAUGUAGCUCAGUGG	18
tRF5-Val-CAC-2-1	6.11	120.86	4.34	20.25	0.00010	0.00151	GCUUCUGUAGUGUAGUGGUUAUCACGUUCG CCUC	34
tRF5-Val-CAC- chr1-93	65.75	869.52	3.72	13.20	0.00056	0.00498	GUUUCCGUAGUGUAGUGGUUAUCACGU UCGCC	32
tRF5-SeC-TCA-2-1	41.06	609.64	3.94	15.34	0.00006	0.00099	AGUGGUCUGGGGUGC	15
tRF5-Leu-AAG-3-1	7.52	247.62	5.12	34.87	0.00000	0.00000	GGUAGCGUGGCCGAGC	16
tRF5-Leu-TAG-3-1	2.23	73.96	5.23	37.54	0.00000	0.00003	GGUAGCGUGGCCGAGU	16
tRF5-Lys-CTT-6-1	27.07	118.09	2.09	4.27	0.01283	0.04915	AGCUCAGUCGGUAGAGCAUGGGACA	25
tRF5-Glu-TTC-1-2	13.42	47.61	1.85	3.60	0.04498	0.12120	AUGGUCUAGCGGUUAGGAUUCCUGGU	26
tRF5-Gly-CCC-6-1	4.71	20.69	2.14	4.39	0.02402	0.07725	AGUGGUAGAAUUCUCGCC	18
tRF5-Glu-TTC-8-1	140.13	1637.50	3.54	11.63	0.00028	0.00287	UCCCCUGUGGUCUAGUGGUUAGGAUUC GGCGCU	33
tRF5-Lys-CTT-3-1	13.01	199.40	3.89	14.80	0.00005	0.00089	GCCCGGCUAGCUCAGUCGGUAGAGCAU GAGACC	33
tRF5-Glu-CTC-2-1	8234.45	83040.94	3.33	10.08	0.00012	0.00173	UCCCUGGUGGUCUAGUGGUUAGGAUUC GGCGCU	33
tRF5-Lys-CTT-2-5	40.64	667.89	4.03	16.29	0.00000	0.00006	GCCCGGCUAGCUCAGUCGGUAGAGCAU GAGACU	33
tRF5-Glu-TTC- chr1-138	82.66	458.76	2.48	5.59	0.00270	0.01595	UCCCUGGUGGUCUAGUGGCUAGGAUUC GGCGCU	33
tRF5-Und-NNN-4-1	9.13	128.84	3.79	13.85	0.00007	0.00117	UCCCUGUAGUCUAGUGGUUAGGAUUCG GCGCU	32

have been found to express the receptor for SARS-CoV-2, therefore, a physiologically relevant cell model to study SARS-CoV-2 (Zhang et al., 2020; Zhu et al., 2020; Schweitzer et al., 2021). Therefore, we also studied tRF5s expression in SAECs in ALI culture. As shown in Figures 5A,B, the cilia were oriented towards the upper transwell compartment, after the cells were in ALI culture for 21 days. The differentiated cultures were infected with SARS-CoV-2 at an MOI of 0.1 for 1 or 3 days, followed by viral S gene quantification using qRT-PCR (Figure 5C). Our qRT-PCR confirmed the expression change in tRF5-GlnCTG and tRF5-ValCAC, two tRFs with relatively low abundance in SARS-CoV-2 positive NPS samples and infected A549-ACE2 cells, can also be detected in SAECs in ALI culture (Figures 5D, E). Since the cleaved tRNAs account for a very tiny portion of parent tRNAs, the difference in the induction folds of tRF5-GlnCTG and tRF5-ValCAC should not be determined by the abundance of their parent tRNAs, but possibly resulted from the distinct sensitivities of their parent tRNAs to the cleavage during the infection. Overall, in this study, we established two cell models, A549-AEC2 cells in monolayer culture and SAECs in ALI culture, to characterize SARS-CoV-2-induced tRFs in the future.

Identification of SARS-CoV-2-Encoded svRNAs

Viral-derived sncRNAs are also an important family of sncRNAs (Tycowski et al., 2015). To investigate whether SARS-CoV-2encoded svRNAs are produced in the context of SARS-CoV-2 infection, the seq data were also aligned to the complete genome sequence of SARS-CoV-2 isolate Wuhan-Hu-1 (NC_045512.2). Several SARS-CoV-2-derived svRNAs were identified in SARS-CoV-2 positive samples. The eight most abundant SARS-CoV-2encoded svRNAs are listed in **Table 6**.

We further analyzed the sequences of svRNAs. Since only RNA <200 bp were selected for the cDNA library, our results should not give svRNAs larger than 200 bp. We found that the length of mapped svRNAs ranged from 17 to 75 nt. Interestingly, svRNAs with the length of 25 nt, 33 nt, and 36 nt were enriched (**Figure 6A**, two representatives are shown). In **Figure 6B**, the locations of the top 8 svRNAs along the SARS-CoV-2 genome are shown.

Experimental Validation of SARS-CoV-2-Encoded svRNAs

Among CoV-2-derived svRNAs (sv-CoV2), a 36 nt sv-CoV2, derived from genomic site 346 to site 382 of nsp1 (sv-CoV2-346) had the highest expression. To further validate the presence of sv-CoV2-346, NPS RNAs from two control samples and two COVID-19 samples were treated with T4 PNK and linked to a 3' RNA linker, and then the RT-PCR was performed. The RT-PCR was also performed without the T4 PNK treatment and RNA linker addition so that the importance of such treatments can be demonstrated. The overall workflow is illustrated in **Figures 1B,C**. The specific 55 nt RT-PCR products of sv-CoV2-346 were observed in SARS-CoV-2 samples, but not in the control samples, when samples were pretreated with T4 PNK and ligated with an RNA linker (**Figure 7A**). The length reflected the 36 nt



sv-CoV2-346 along with the 3' RNA linker. In addition, we found that the RT-PCR product of one SARS-CoV-2 sample was more than another one, which was consistent with their read frequency in Seq-data. The presence of sv-CoV2-346 was confirmed in SARS-CoV-2-infected A549-ACE2 cells using RT-PCR (**Figure 7B**).

Coronavirus-encoded svRNAs have been previously reported to be 18–22 nt long and therefore, share similar lengths with miRNAs (Morales et al., 2017; Cheng et al., 20212021). Coronavirus-encoded svRNAs with lengths longer than 30 nt have not been identified. Herein, we think that the identification of additional SARS-CoV-2-derived svRNAs was benefited from the treatment of T4 PNK and RNA linker ligation at their 3'-end. As shown in **Figure 7C**, both patient or infected cell samples, without such treatments, did not result in the band presence, supporting the lack of 3'-OH end of sv-CoV2-346 and the necessity of specific T4 PNK treatment for sv-CoV2-346 detection.

Herein, we also initialed to characterize sv-CoV2-346 by predicting the secondary RNA structure of svRNAs. Besides sv-CoV2-346, there were two other svRNAs, sv-CoV2-299 and svCoV2-404, near the region where sv-CoV-346 was derived

(Table 7). sv-CoV2-299, sv-CoV2-346, and sv-CoV2-404 were derived from nucleotide 299 to 328, 346 to 382, and 400 to 443, respectively. Therefore, we took the viral genome spanning from 289 to 485, which covers all these three regions with some nt extension on both ends and predicted its RNA secondary structure using RNAfold web server based on minimum free energy to have a clue of biogenesis mechanisms (Hofacker, 2003) (Figure 8A). We found that nucleotides 299, 328, 400, 443, and 382 are all located on loops, implying the cleavage at these five sites along with the single-stranded RNA by ribonuclease (Figure 8A). Only nucleotide 346 was in the middle of the stem (Figure 8A). Interestingly, we found that 68 nt long (sv-CoV2-314) overlapped with sv-CoV2-346 svRNAs (Table 7). We, therefore, took the genome section spanning from 314 to 382 and run the secondary and tertiary structures of sv-CoV2-314 using RNAfold web server and RNAComposer, respectively (Hofacker, 2003; Popenda et al., 2012) (Figures 8B,C). This 68 nt fragment contained three hairpin loops and was folded into an L-shaped-like tertiary structure, and nucleotide 346 was located within the bottom loop (Figures 8B,C). The secondary and tertiary structures of sv-CoV2-314 were similar to tRNA, and nucleotide 346 location was similar to



the cleavage site of tRFs (**Figures 8D,E**). Thus, we speculated that 68 nt sv-CoV2-314 may be the precursor of 36 nt sv-CoV2-346 and the virus may use endonuclease involved in tRF biogenesis to generate viral small RNAs fragments.

DISCUSSION

In this study, we identified the change in sncRNA expression by SARS-CoV-2. Among sncRNAs, miRNAs have been getting lots of attention in the studies (Vaz et al., 2010; Plieskatt et al., 2014; Max et al., 2018; Hou and Yao, 2021). Standard barcode-ligationbased small RNA-seq are usually designed to capture miRNAs, which usually have 3'-OH ends (Hafner et al., 2008). It is increasingly acknowledged that the 3'-ends of other types of sncRNAs are heterogeneous (Honda et al., 2015), resulting in unsuccessful sequencing barcode ligation in the standard small RNA-seq. In our study, T4 PNK-RNA-seq was employed to profile sncRNAs with heterogeneous ends. Sequencing data revealed that piRNAs and tRFs had higher global expression than miRNAs in NPS (**Figure 2A**). sncRNAs may carry various unidentified modifications, which are insensitive to T4 PNK treatment. Therefore, T4 PNK-RNA-seq may leave some SARS-CoV-2-impacted sncRNAs unidentified. Herein, the consistency among the seq data, qRT-PCR result, and NB data of tRF5-GluCTC suggested the reliability of T4 PNK-RNA-seq for tRF5 detection.

Notable, among differently expressed tRF5s with mean of normalized counts >20 in control (CN) or SARS-CoV-2 groups (**Table 5**), we found four tRF5s: tRF5-GluTTC-1-2, tRF5-GlyCCC-6-1, tRF5-LysCTT61 and tRF5-SecTCA-2-1, were not classic tRF5s. While their 3'-ends commonly stop around the anticodon region like classical tRF5s, they lack the first 10-15 nt of the tRNA 5'end. Since they span the complete region of the D loop and the first half of the anticodon loop, we subgrouped and named them as tRF5DC (**Supplementary Figure S2**). Interestingly, tRF5DC and classic tRF5s were derived from the different tRNA isoacceptors tRNA, suggesting different biogenesis mechanisms of these two type tRFs.

This study further supported that tRFs induction is virusspecific. Previously, we and others have shown that RSV, hepatitis B virus (HBV), and hepatitis C virus (HCV) infections lead to



insert was fixed with 4% polyoxymethylene, followed by tissue processing, sectioning, and H&E staining. (B) Transmission electron microscopy (TEM) of SAECs in ALI culture of ALCs were apically infected with SARS-CoV-2 at an MOI of 0.1 for 1 or 3 days, qRT-PCR was performed to detect SARS-CoV-2 s gene expression. GAPDH was used as an internal control. (D,E) on day 3 postinfection, tRF5-GINCTG (D) and tRF5-VaICAC (E) expressions were measured using qRT-PCR. Mock-infected cells were used as control (CN). Unpaired two-tailed t-tests were performed for statistical comparisons. Single asterisks represent *p* values of <0.05. Data are shown as means ± SE and are representative of three independent experiments.

TABLE 6 SARS-0	ABLE 6 SARS-CoV-2-encoded svRNAs.											
sv-CoV2 small	G enome	a enome Sequence		Derived ORFs of SARS	Raw reads							
RNAs	position		(nt)	CoV-2	Sample 1	Sample 2						
sv-CoV2-346	346–382	CGUACGUGGCUUUGGAGACUCCGUGGAGGA GGUCUU	36	nsp1	43071	3258						
sv-CoV2-2825	2,825-2,861	AAUGAGAAGUGCUCUGCCUAUACAGUUGAACUCGGU	36	nsp3	13535	4426						
sv-CoV2-6286	6,286–6,311	CUGGUGUAUACGUUGUCUUUGGAGC	25	nsp3	11743	2939						
sv-CoV2-14728	14,728–14,751	AAGGAAGGAAGUUCUGUUGAAUU	23	nsp12	2026	2188						
sv-CoV2-15954	15,954–15,979	AGGGGCCGGCUGUUUUGUAGAUGAU	25	nsp12	10998	1846						
sv-CoV2-20364	20,364–20,415	ACAUCUACUGAUUGGACUAGCUAAACGUUUUAAGGA AUCACCUUUUGAAUU	51	nsp15	10510	3422						
sv-CoV2-21145	21,145–21,171	CUUGGAGGUUCCGUGGCUAUAAAGAU	26	nsp16	3134	1394						
sv-CoV2-26183	26,183–26,216	AUGAUGAACCGACGACGACUACUAGCGUGCCUU	33	3a	15134	4925						



FIGURE 6 | Sequence information of virus-derived sncRNAsA. (A) Length distribution of viral small RNAs from two representative patient samples. (B) Two representative visual inspections of the small RNA sequences aligning with the SARS-CoV-2 genome. The names of viral genes and the genome positions (nt) are indicated.

different tRF profile changes (Wang et al., 2013; Selitsky et al., 2015; Zhou et al., 2017; Choi et al., 2020). Compared with tRF induction by RSV, we found that SARS-CoV-2 could induce tRF5-ValCAC, while RSV cannot. On the other hand, we found that tRF5-GlyGCC, which is significantly inducible by RSV, was not induced by SARS-CoV-2. The virus-specific changes in tRFs suggest them to be promising biomarkers for viral infections.

Other than host-derived sncRNAs, sncRNAs can also be derived from viruses. svRNAs have been reported to be involved in the regulation of viral replication, viral persistence, host immune evasion, and cellular transformation (Tycowski et al., 2015). SARS-CoV-2-encoded sncRNAs have been demonstrated by two independent groups (Cheng et al., 20212021; Fu et al., 2021). Using T4-PNK-RNA-seq, several novel svRNAs in SARS-CoV-2 NPS samples were identified. One of them, sv-CoV2-346, was verified to be present in SARS-CoV-2-infected A549-ACE2 cells as well. Due to the limited NPS RNA samples, the leftover RNAs after sequencing were not enough for stem-loop qRT-PCR to validate svRNAs. Thus, we detected sv-CoV2-346 by RT-PCR using the same cDNA generated by the RT step for the qRT-PCR assays for tRF5s. Our RT-PCR revealed a sv-CoV2-346 specific band around 55 nt and a non-specific band. In the future, we will

study the relationship between SARS-CoV-2 svRNAs and viral loads/disease severity.

The most widely studied viral sncRNAs are miRNAs-like svRNAs. Both DNA and RNA viruses could encode miRNAslike svRNAs via Dicer-dependent miRNAs biogenesis pathways (Tycowski et al., 2015; Grundhoff and Sullivan, 2011). Among RNA viruses, cytoplasmic restricted RNA viruses were thought incapable of producing miRNA-like svRNAs. However, accumulating evidence indicates cytoplasmic RNA viruses, such as H5N1 influenza virus, enterovirus 71(EV71), West Nile virus (WNV), SARS-CoV, and SARS-CoV-2, also encode viral miRNAs (Morales et al., 2017; Cheng et al., 20212021; Fu et al., 2021; Perez et al., 2010; Li et al., 2018; Weng et al., 2014; Hussain et al., 2012). These cytoplasmic RNA viruses generate viral miRNAs via multiple non-canonical miRNAs biogenesis mechanisms. Dicer, not Drosha, is involved in WNV and EV71 viral miRNAs generation (Weng et al., 2014; Hussain et al., 2012). H5N1 influenza virus and SARS-CoV encode viral miRNAs in a Dicer-and Drosha-independent way (Morales et al., 2017; Li et al., 2018). Besides viral miRNAs, the induction of functional svRNAs, which do not look like miRNAs, was reported for cytoplasmic RNA viruses (Perez et al., 2010). However, the knowledge on how cytoplasmic RNA viruses produce svRNAs is limited. One of the



 TABLE 7 | RNA sequence information for those with high raw reads and mapping to viral nucleotides 289–485.

sv-CoV2 small RNAs Genome		Sequence	Length	Raw reads	
fragments	position		(nt)	Sample 1	Sample 2
sv-CoV2-346	346–382	CGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUU	36	43,071	3,036
sv-CoV2-299	299–328	ACACACGUCCAACUCAGUUUGCCUGUUUU	29	1,931	636
sv-CoV2-404	404-443	AAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGC	39	1,311	586
sv-CoV2-314	314–382	AGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGA GACUCCGUGG AGGAGGUCUU	68	126	13

interesting observations of newly discovered sv-CoV2 is that sv-CoV2-314 may have a similar tertiary structure as tRNAs and function as the potential precursor of 36 nt svCoV2-346 (**Figure 8**). Whether a tRNA-like shape (three-leafed clover) of svRNAs makes them as prone as tRNAs to the cleavage during SARS-CoV-2 infection will be investigated in the future. Recently, the cleavage of tRNAs has been reported to be regulated by nt

modifications and tRNA anticodon loop is enriched with modification (Blanco et al., 2014; Ranjan and Rodnina, 2016). Therefore, it is possible that the anticodon and/or D loop experience nt modification changes in SARS-CoV-2 infection, resulting in the cleavage. It has been also previously reported that the cleavage of tRNAs is mediated by specific ribonuclease(s) (Lee et al., 2009; Wang et al., 2013; Zhou et al., 2017; Choi et al., 2020).



Therefore, it is also possible SARS-CoV-2 favors the activation of certain enzymes to enrich the corresponding sncRNA population. How viruses use the host proteins to control the biogenesis of sncRNAs is still unclear and awaits investigation.

In summary, we investigated COVID-19-impacted sncRNAs comprehensively using the NPS samples by T4 PNK-RNA-seq and modified qRT-PCR method. We are aware that our study has some limitations. For example, T4 PNK-RNA-seq may not catch all types of sncRNAs. In addition, our NPS samples were all from outpatient clinics, which set the limitation to study the correlation of tRF changes with the disease severity. We are closely working with our Molecular Diagnosis Laboratory to obtain the samples from outpatient, inpatient, and ICU services so that whether tRFs serve as disease biomarkers can be determined. Our recent publication on the correlation of tRF changes with Alzheimer's disease severity supports tRFs to be promising disease biomarkers (Wu et al., 2021). Other than biomarkers, the studies of tRFs in viral infections may also provide insight into therapeutic/prophylactic strategy development. In RSV infection, we found some induced tRFs promote viral replication (Wang et al., 2013; Zhou et al., 2017; Choi et al., 2020). Therefore, any mechanisms associated with their biogenesis and function would not only reveal potential targets to control viral replication but also benefit the ncRNA research community.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: Gene Expression Omnibus accession number: GSE193555.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by University of Texas Medical. IRB committee. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

WW and XB wrote the manuscript; WW, E-JC, BW, KZ, contributed to the experiment performance and data analyses. LT, PH, RG, II, LH, and IL contribute to the deep seq data analyses and related methodology establishment. GH and JD developed IBM protocols for sample collection and NSP sample handling. JD, TW, and XB contributed to overall project management and experimental design.

FUNDING

This work was supported by grants from the NIH R01 AI116812, R21AG069226, and Research Pilot Grant from the Institute for Human Infections and Immunity (IHII) at UTMB to XB and NIH grants R01AI127744 (TW), R21 AI140569 (TW), and R21 EY029112 (TW).

ACKNOWLEDGMENTS

We thank Darby L. Buck for the manuscript editing.

REFERENCES

- Beermann, J., Piccoli, M.-T., Viereck, J., and Thum, T. (2016). Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches. *Physiol. Rev.* 96, 1297–1325. doi:10.1152/ physrev.00041.2015
- Bhowmick, R., and Gappa-Fahlenkamp, H. (2016). Cells and Culture Systems Used to Model the Small Airway Epithelium. *Lung* 194, 419–428. doi:10.1007/ s00408-016-9875-2
- Blanco, S., Dietmann, S., Flores, J. V., Hussain, S., Kutter, C., Humphreys, P., et al. (2014). Aberrant Methylation of T RNA S Links Cellular Stress to Neurodevelopmental Disorders. *EMBO J.* 33, 2020–2039. doi:10.15252/embj. 201489282
- Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., et al. (2020). Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. *Cell* 181, 1036–1045. doi:10.1016/j.cell.2020. 04.026
- Buchrieser, J., Dufloo, J., Hubert, M., Monel, B., Planas, D., Rajah, M. M., et al. (2021). Syncytia Formation by SARS-CoV-2-Infected Cells. *EMBO J.* 40, e107405. doi:10.15252/embj.2020107405
- Chandorkar, P., Posch, W., Zaderer, V., Blatzer, M., Steger, M., Ammann, C. G., et al. (2017). Fast-track Development of an *In Vitro* 3D Lung/immune Cell Model to Study Aspergillus Infections. *Sci. Rep.* 7, 11644. doi:10.1038/s41598-017-11271-4
- Cheng, Z., Cheng, L., Lin, J., Lunbiao, C., Chunyu, L., Guoxin, S., et al. (20212021). Verification of SARS-CoV-2-Encoded Small RNAs and Contribution to Infection-Associated Lung Inflammation. *bioRxiv* 2005, 444324. doi:10.1101/ 2021.05.16.444324
- Choi, E. J., Wu, W., Zhang, K., Lee, I., Kim, I. H., Lee, Y. S., et al. (2020). ELAC2, an Enzyme for tRNA Maturation, Plays a Role in the Cleavage of a Mature tRNA to Produce a tRNA-Derived RNA Fragment during Respiratory Syncytial Virus Infection. Front. Mol. Biosci. 7, 609732. doi:10.3389/fmolb.2020.609732
- Choudhuri, S. (2010). Small Noncoding RNAs: Biogenesis, Function, and Emerging Significance in Toxicology. J. Biochem. Mol. Toxicol. 24, 195–216. doi:10.1002/jbt.20325
- Dozmorov, M. G., Giles, C. B., Koelsch, K. A., and Wren, J. D. (2013). Systematic Classification of Non-coding RNAs by Epigenomic Similarity. BMC Bioinformatics 14 Suppl 14 (Suppl. 14), S2. doi:10.1186/1471-2105-14-S14-S2
- Fabian, M. R., and Sonenberg, N. (2012). The Mechanics of miRNA-Mediated Gene Silencing: a Look under the Hood of miRISC. *Nat. Struct. Mol. Biol.* 19, 586–593. doi:10.1038/nsmb.2296
- Fu, H., Feng, J., Liu, Q., Sun, F., Tie, Y., Zhu, J., et al. (2009). Stress Induces tRNA Cleavage by Angiogenin in Mammalian Cells. *FEBS Lett.* 583, 437–442. doi:10. 1016/j.febslet.2008.12.043
- Fu, Z., Wang, J., Wang, Z., Sun, Y., Wu, J., Zhang, Y., et al. (2021). A Virus-Derived microRNA-like Small RNA Serves as a Serum Biomarker to Prioritize the COVID-19 Patients at High Risk of Developing Severe Disease. *Cell Discov* 7, 48. doi:10.1038/s41421-021-00289-8
- Giraldez, M. D., Spengler, R. M., Etheridge, A., Goicochea, A. J., Tuck, M., Choi, S. W., et al. (2019). Phospho-RNA-seq: a Modified Small RNA-Seq Method that Reveals Circulating mRNA and lncRNA Fragments as Potential Biomarkers in Human Plasma. *EMBO J.* 38.e101695. doi:10.15252/embj.2019101695

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmolb.2022.821137/full#supplementary-material

Supplementary Figure 1 | The pipeline of T4 PNK-RNA-seq and data analyses. (A) The flowchart of T4 PNK-RNA-seq. (B) The flowchart of the sequencing data analyses.

Supplementary Figure 2 | Biogenesis of tRF5s and tRF5DC. tRF5s are generated by the cleavage on the anticodon loop (black arrows); tRF5DCs are derived from the cleavage on the D arm (red or blue arrow) and anticodon loop (black arrows).

- Grundhoff, A., and Sullivan, C. S. (2011). Virus-encoded microRNAs. Virology 411, 325–343. doi:10.1016/j.virol.2011.01.002
- Hafner, M., Landgraf, P., Ludwig, J., Rice, A., Ojo, T., Lin, C., et al. (2008). Identification of microRNAs and Other Small Regulatory RNAs Using cDNA Library Sequencing. *Methods* 44, 3–12. doi:10.1016/j.ymeth.2007.09.009
- Hasan, M. M., Akter, R., Ullah, M. S., Abedin, M. J., Ullah, G. M., and Hossain, M. Z. (2014). A Computational Approach for Predicting Role of Human MicroRNAs in MERS-CoV Genome. *Adv. Bioinformatics* 2014, 967946. doi:10.1155/2014/967946
- Hiemstra, P. S., Grootaers, G., van der Does, A. M., Krul, C. A. M., and Kooter, I. M. (2018). Human Lung Epithelial Cell Cultures for Analysis of Inhaled Toxicants: Lessons Learned and Future Directions. *Toxicol. Vitro* 47, 137–146. doi:10. 1016/j.tiv.2017.11.005
- Hofacker, I. L. (2003). Vienna RNA Secondary Structure Server. *Nucleic Acids Res.* 31, 3429–3431. doi:10.1093/nar/gkg599
- Honda, S., Loher, P., Shigematsu, M., Palazzo, J. P., Suzuki, R., Imoto, I., et al. (2015). Sex Hormone-dependent tRNA Halves Enhance Cell Proliferation in Breast and Prostate Cancers. *Proc. Natl. Acad. Sci. USA* 112, E3816–E3825. doi:10.1073/pnas.1510077112
- Hou, J., and Yao, C. (2021). Potential Prognostic Biomarkers of Lung Adenocarcinoma Based on Bioinformatic Analysis. *Biomed. Res. Int.* 2021, 8859996. doi:10.1155/2021/8859996
- Hussain, M., Torres, S., Schnettler, E., Funk, A., Grundhoff, A., Pijlman, G. P., et al. (2012). West Nile Virus Encodes a microRNA-like Small RNA in the 3' Untranslated Region Which Up-Regulates GATA4 mRNA and Facilitates Virus Replication in Mosquito Cells. *Nucleic Acids Res.* 40, 2210–2223. doi:10.1093/nar/gkr848
- Ivanov, P., O'Day, E., Emara, M. M., Wagner, G., Lieberman, J., and Anderson, P. (2014). G-quadruplex Structures Contribute to the Neuroprotective Effects of Angiogenin-Induced tRNA Fragments. *Proc. Natl. Acad. Sci. USA* 111, 18201–18206. doi:10.1073/pnas.1407361111
- Karolchik, D., Hinrichs, A. S., Furey, T. S., Roskin, K. M., Sugnet, C. W., Haussler, D., et al. (2004). The UCSC Table Browser Data Retrieval Tool. *Nucleic Acids Res.* 32, D493–D496. doi:10.1093/nar/gkh103
- Khan, M. A.-A. -K., Sany, M. R. U., Islam, M. S., and Islam, A. B. M. M. K. (2020). Epigenetic Regulator miRNA Pattern Differences Among SARS-CoV, SARS-CoV-2, and SARS-CoV-2 World-wide Isolates Delineated the Mystery behind the Epic Pathogenicity and Distinct Clinical Characteristics of Pandemic COVID-19. Front. Genet. 11, 765. doi:10.3389/fgene.2020.00765
- Lee, Y. S., Shibata, Y., Malhotra, A., and Dutta, A. (2009). A Novel Class of Small RNAs: tRNA-Derived RNA Fragments (tRFs). *Genes Dev.* 23, 2639–2649. doi:10.1101/gad.1837609
- Li, X., Fu, Z., Liang, H., Wang, Y., Qi, X., Ding, M., et al. (2018). H5N1 Influenza Virus-specific miRNA-like Small RNA Increases Cytokine Production and Mouse Mortality via Targeting poly(rC)-Binding Protein 2. *Cell Res* 28, 157–171. doi:10.1038/cr.2018.3
- Liu, S., Chen, Y., Ren, Y., Zhou, J., Ren, J., Lee, I., et al. (2018). A tRNA-Derived RNA Fragment Plays an Important Role in the Mechanism of Arsenite -induced Cellular Responses. *Sci. Rep.* 8, 16838. doi:10.1038/s41598-018-34899-2
- Mallick, B., Ghosh, Z., and Chakrabarti, J. (2009). MicroRNome Analysis Unravels the Molecular Basis of SARS Infection in Bronchoalveolar Stem Cells. *PLoS One* 4, e7837. doi:10.1371/journal.pone.0007837

- Max, K. E. A., Bertram, K., Akat, K. M., Bogardus, K. A., Li, J., Morozov, P., et al. (2018). Human Plasma and Serum Extracellular Small RNA Reference Profiles and Their Clinical Utility. *Proc. Natl. Acad. Sci. USA* 115, E5334–E5343. doi:10. 1073/pnas.1714397115
- Morales, L., Oliveros, J. C., Fernandez-Delgado, R., tenOever, B. R., Enjuanes, L., and Sola, I. (2017). SARS-CoV-Encoded Small RNAs Contribute to Infection-Associated Lung Pathology. *Cell Host & Microbe* 21, 344–355. doi:10.1016/j. chom.2017.01.015
- Mossel, E. C., Huang, C., Narayanan, K., Makino, S., Tesh, R. B., and Peters, C. J. (2005). Exogenous ACE2 Expression Allows Refractory Cell Lines to Support Severe Acute Respiratory Syndrome Coronavirus Replication. J. Virol. 79, 3846–3850. doi:10.1128/jvi.79.6.3846-3850.2005
- Perez, J. T., Varble, A., Sachidanandam, R., Zlatev, I., Manoharan, M., Garcia-Sastre, A., et al. (2010). Influenza A Virus-Generated Small RNAs Regulate the Switch from Transcription to Replication. *Proc. Natl. Acad. Sci.* 107, 11525–11530. doi:10.1073/pnas.1001984107
- Plieskatt, J. L., Rinaldi, G., Feng, Y., Levine, P. H., Easley, S., Martinez, E., et al. (2014). Methods and Matrices: Approaches to Identifying miRNAs for Nasopharyngeal Carcinoma. J. Transl Med. 12, 3. doi:10.1186/1479-5876-12-3
- Popenda, M., Szachniuk, M., Antczak, M., Purzycka, K. J., Lukasiak, P., Bartol, N., et al. (2012). Automated 3D Structure Composition for Large RNAs. *Nucleic Acids Res.* 40, e112. doi:10.1093/nar/gks339
- Qin, C., Xu, P. P., Zhang, X., Zhang, C., Liu, C. B., Yang, D. G., et al. (2020). Pathological Significance of tRNA-Derived Small RNAs in Neurological Disorders. *Neural Regen. Res.* 15, 212–221. doi:10.4103/1673-5374.265560
- Rajput, R., Sharma, J., Nair, M. T., Khanna, M., Arora, P., and Sood, V. (2020). Regulation of Host Innate Immunity by Non-coding RNAs during Dengue Virus Infection. Front. Cel. Infect. Microbiol. 10, 588168. doi:10.3389/fcimb.2020.588168
- Ranjan, N., and Rodnina, M. V. (2016). tRNA Wobble Modifications and Protein Homeostasis. *Translation* 4, e1143076. doi:10.1080/21690731.2016.1143076
- Romano, G., Veneziano, D., Acunzo, M., and Croce, C. M. (2017). Small Noncoding RNA and Cancer. *Carcinogenesis* 38, 485–491. doi:10.1093/carcin/ bgx026
- Schwarz, D. S., Tomari, Y., and Zamore, P. D. (2004). The RNA-Induced Silencing Complex Is a Mg2+-dependent Endonuclease. *Curr. Biol.* 14, 787–791. doi:10. 1016/j.cub.2004.03.008
- Schweitzer, K. S., Crue, T., Nall, J. M., Foster, D., Sajuthi, S., Correll, K. A., et al. (2021). Influenza Virus Infection Increases ACE2 Expression and Shedding in Human Small Airway Epithelial Cells. *Eur. Respir. J.* 58, 2003988. doi:10.1183/ 13993003.03988-2020
- Selitsky, S. R., Baran-Gale, J., Honda, M., Yamane, D., Masaki, T., Fannin, E. E., et al. (2015). Small tRNA-Derived RNAs Are Increased and More Abundant Than microRNAs in Chronic Hepatitis B and C. Sci. Rep. 5, 7675. doi:10.1038/ srep07675
- Shen, Y., Yu, X., Zhu, L., Li, T., Yan, Z., and Guo, J. (2018). Transfer RNA-Derived Fragments and tRNA Halves: Biogenesis, Biological Functions and Their Roles in Diseases. J. Mol. Med. 96, 1167–1176. doi:10.1007/s00109-018-1693-y
- Sun, C., Fu, Z., Wang, S., Li, J., Li, Y., Zhang, Y., et al. (2018). Roles of tRNA-Derived Fragments in Human Cancers. *Cancer Lett.* 414, 16–25. doi:10.1016/j. canlet.2017.10.031
- Tycowski, K. T., Guo, Y. E., Lee, N., Moss, W. N., Vallery, T. K., Xie, M., et al. (2015). Viral Noncoding RNAs: More Surprises. *Genes Dev.* 29, 567–584. doi:10.1101/gad.259077.115
- Vaz, C., Ahmad, H. M., Sharma, P., Gupta, R., Kumar, L., Kulshreshtha, R., et al. (2010). Analysis of microRNA Transcriptome by Deep Sequencing of Small

RNA Libraries of Peripheral Blood. BMC Genomics 11, 288. doi:10.1186/1471-2164-11-288

- Wang, Q., Lee, I., Ren, J., Ajay, S. S., Lee, Y. S., and Bao, X. (2013). Identification and Functional Characterization of tRNA-Derived RNA Fragments (tRFs) in Respiratory Syncytial Virus Infection. *Mol. Ther.* 21, 368–379. doi:10.1038/ mt.2012.237
- Weng, K.-F., Hung, C.-T., Hsieh, P.-T., Li, M.-L., Chen, G.-W., Kung, Y.-A., et al. (2014). A Cytoplasmic RNA Virus Generates Functional Viral Small RNAs and Regulates Viral IRES Activity in Mammalian Cells. *Nucleic Acids Res.* 42, 12789–12805. doi:10.1093/nar/gku952
- Weston, S., Coleman, C. M., Haupt, R., Logue, J., Matthews, K., Li, Y., et al. (2020). Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 *In Vitro* and SARS-CoV *In Vivo. J. Virol.* 94, e01218. doi:10.1128/JVI.01218-20
- World Health, O. (2021). World Health Organization. Geneva.
- Wu, W., Choi, E. J., Lee, I., Lee, Y. S., and Bao, X. (2020) Non-Coding RNAs and Their Role in Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Infections. 12(3):345.doi:10.3390/v12030345
- Wu, W., Lee, I., Spratt, H., Fang, X., and Bao, X. (2021). tRNA-Derived Fragments in Alzheimer's Disease: Implications for New Disease Biomarkers and Neuropathological Mechanisms. Jad 79, 793-806. doi:10.3233/jad-200917
- Zhang, H., Rostami, M. R., Leopold, P. L., Mezey, J. G., O'Beirne, S. L., Strulovici-Barel, Y., et al. (2020). Expression of the SARS-CoV-2 ACE2 Receptor in the Human Airway Epithelium. Am. J. Respir. Crit. Care Med. 202, 219–229. doi:10. 1164/rccm.202003-0541oc
- Zhou, J., Liu, S., Chen, Y., Fu, Y., Silver, A. J., Hill, M. S., et al. (2017). Identification of Two Novel Functional tRNA-Derived Fragments Induced in Response to Respiratory Syncytial Virus Infection. J. Gen. Virol. 98, 1600–1610. doi:10.1099/ jgv.0.000852
- Zhu, L., Liu, X., Pu, W., and Peng, Y. (2018). tRNA-derived Small Non-coding RNAs in Human Disease. *Cancer Lett.* 419, 1–7. doi:10.1016/j.canlet.2018. 01.015
- Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., et al. (2020). A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733. doi:10.1056/nejmoa2001017

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wu, Choi, Wang, Zhang, Adam, Huang, Tunkle, Huang, Goru, Imirowicz, Henry, Lee, Dong, Wang and Bao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.